Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits

Busse, A.; Kraus, M.; Na, I.K.; Rietz, A.; Scheibenbogen, C.; Driessen, C.; Blau, I.W.; Thiel, E.; Keilholz, U.

Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits

Tools

Item Type:	Article
Title:	Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits
Creators Name:	Busse, A., Kraus, M., Na, I.K., Rietz, A., Scheibenbogen, C., Driessen, C., Blau, I.W., Thiel, E. and Keilholz, U.
Abstract:	Background: Sensitivity of tumor cells to induction of apoptosis by proteasome inhibitors varies greatly. This study was undertaken to investigate the sensitivity of neoplastic B cells and solid tumor cells to proteasome inhibition with respect to constitutive expression levels of proteasome subunits. Methods: Twelve neoplastic B-cell lines and 12 solid tumor cell lines were assessed for their expression levels of proteasome subunits by using quantitative reverse transcriptase-polymerase chain reaction analysis and were assessed for their sensitivity to the proteasome inhibitors PS-341 and lactacystin by using a flow cytometry assay that detected activated caspases. Results: The neoplastic B-cell lines were categorized into 3 groups representing refractory cell lines, cell lines with moderate sensitivity, and cell lines with high sensitivity. Correlating expression levels of proteasome subunits with sensitivity to proteasome inhibition indicated that refractory B cells exhibited lower expression levels of the standard subunit beta2 and of the immunoproteasome subunit LMP2 compared with sensitive B cell lines. Compared with neoplastic B cells solid tumor cells were less sensitive. They expressed the immunoproteasome subunits LMP2, LMP7 and MECL-1 and the standard subunit beta2 clearly below the median of the expression level of the sensitive B cell lines. IFN-gamma pretreatment enhanced sensitivity to PS-341 in 50% of the tumor cell lines, potentially related to the induction of immunoproteasomes. Conclusions: The results of this study indicated that sensitivity to proteasome inhibition is correlated with expression levels of proteasome subunits, which determine the enzymatic activity of the proteasome. Combining PS-341 with IFN-gamma may enhance its clinical efficacy.
Keywords:	Apoptosis Induction, Proteasome Inhibition, PS-341, Solid Tumors, B-Cell Neoplasia, Interferon {gamma}
Source:	Cancer
ISSN:	0008-543X
Publisher:	Wiley
Volume:	112
Number:	3
Page Range:	659-670
Date:	1 February 2008
Official Publication:	https://doi.org/10.1002/cncr.23224
PubMed:	View item in PubMed

Repository Staff Only: item control page